Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma

Xi Zhang; Liqiong Wang; Shu Chen; Peng Huang; Lan Ma; Hui Ding; Basappa Basappa; Tao Zhu; Peter E. Lobie; Vijay Pandey

doi:10.1038/s43856-022-00142-3

Communications Medicine (Jul 2022)

Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma

Xi Zhang,
Liqiong Wang,
Shu Chen,
Peng Huang,
Lan Ma,
Hui Ding,
Basappa Basappa,
Tao Zhu,
Peter E. Lobie,
Vijay Pandey

Affiliations

Xi Zhang: Shenzhen Bay Laboratory, Shenzhen
Liqiong Wang: Department of Gynecology and Obstetrics, the University of Hong Kong-Shenzhen Hospital, Shenzhen
Shu Chen: Tsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University
Peng Huang: Tsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University
Lan Ma: Shenzhen Bay Laboratory, Shenzhen
Hui Ding: Department of Gynecology and Obstetrics, The Second Xiangya Hospital of Central South University
Basappa Basappa: Department of Studies in Organic Chemistry, University of Mysore
Tao Zhu: Department of Oncology of the First Affiliated Hospital, Division of Life Sciences and Medicine, University of Science and Technology of China
Peter E. Lobie: Shenzhen Bay Laboratory, Shenzhen
Vijay Pandey: Tsinghua Berkeley Shenzhen Institute, Tsinghua Shenzhen International Graduate School, Tsinghua University

DOI: https://doi.org/10.1038/s43856-022-00142-3
Journal volume & issue: Vol. 2, no. 1
pp. 1 – 16

Abstract

Read online

Zhang et al. test the therapeutic potential of an inhibitor of BAD phosphorylation, NPB, in epithelial ovarian cancer. The authors show that the small molecule synergises with PARP inhibition to kill patient-derived ovarian cancer organoids and suppress the growth of xenograft tumours, including a cisplatin-resistant model.

Published in Communications Medicine

ISSN: 2730-664X (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Medicine
Website: https://www.nature.com/commsmed/

About the journal